Progressive Multifocal Leukoencephalopathy as a Complication of Hepatitis C Virus Treatment in an HIV-Negative Patient

Authors:

Abstract
SIR—It is estimated that >170 million individuals are infected with hepatitis C virus (HCV) worldwide. To date, combination therapy with pegylated IFN-α 2a or 2b and ribavirin has been shown to be the most effective treatment and can eradicate HCV in >50% of affected individuals [1]. However, serious side effects are associated with this treatment, including leukopenia and a potential risk of opportunistic infections [2, 3]. We describe a patient who developed progressive multifocal leukoencephalopathy (PML) while receiving pegylated IFN-α and ribavirin therapy for HCV infection.

This publication has 8 references indexed in Scilit: